NCT03328273 2026-04-20
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
Phase 1 Active not recruiting
Acerta Pharma BV
National Cancer Institute (NCI)
AstraZeneca
AstraZeneca
University of Leeds
Massachusetts General Hospital
Royal Marsden NHS Foundation Trust